Here, using two distinct gene expression databases, each containing information from more than 1900 breast cancer patients, we found that high PAK4 expression consistently correlated with poor outcome for endocrine treatment and specifically tamoxifen treated breast cancer patients, while the expression of other PAK family members did not consistently display such correlation in both databases. This evidence concerns the gene PAK4 and breast carcinoma.